# Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

Source: https://onco.cc/trials/nct06754085/  
OnCo record `nct06754085` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Florastamin[18F] Injection in prostate cancer, run by HTA Co., Ltd., now recruiting.

## Summary

Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06754085 by HTA Co., Ltd., with 131 participants planned, started 2024-12-19 and due to reach its primary completion in 2026-01-01. Interventions recorded: Florastamin[18F] Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06754085
- Phase: 3
- Setting: A Phase III, Prospective, Open-Label, Single-Arm, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
- Sponsor: HTA Co., Ltd.
- Enrolled: 131

## Sources

- ClinicalTrials.gov NCT06754085: https://clinicaltrials.gov/study/NCT06754085

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06754085.json